Amarin Clearly and Definitively Instructed Registrar to Accept ALL Submitted Proxy Cards
February 16 2023 - 09:44AM
Amarin Corporation plc (NASDAQ: AMRN) (“Amarin” or the “Company”)
today corrected the record regarding the latest misinformation from
Sarissa Capital Management (“Sarissa”). Contrary to Sarissa’s press
release, Amarin clearly and definitively instructed its registrar
to accept ALL submitted proxy cards, including both blue and white
cards, with regard to its upcoming General Meeting of Shareholders.
This is standard practice for a contested solicitation process and
was established before the proxy solicitation process even began.
The idea that a company registrar would only accept one set of
proxy cards is categorically false.
This is yet another example of Sarissa's focus on advancing its
own interests at the expense of all Amarin shareholders. The
registrar confirmed that it notified Sarissa eight hours in advance
of their press release that all proxy cards were being considered.
It is clear that Sarissa is willing to say anything in an attempt
to get on the Board.
In a note dated February 16, 2023, from the registrar:
“As mentioned, [the registrar] did
not advise [Sarissa] that Amarin were not accepting these proxy
cards. As this was a different proxy form that [the registrar] had
seen before, we had to check with Amarin if we were to accept it.
Amarin advised that we were able to accept therefore we have lodged
As this confirmation shows, the registrar was clearly instructed
to accept all proxy cards, including Sarissa’s blue proxy card.
Materials regarding the Board of Directors’ recommendations for
the General Meeting can be found at www.voteamarin.com.
Amarin is an innovative pharmaceutical company leading a new
paradigm in cardiovascular disease management. From our foundation
in scientific research to our focus on clinical trials, and now our
commercial expansion, we are evolving and growing rapidly. Amarin
has offices in Bridgewater, New Jersey in the United States, Dublin
in Ireland, Zug in Switzerland, and other countries in Europe as
well as commercial partners and suppliers around the world. We are
committed to increasing the scientific understanding of the
cardiovascular risk that persists beyond traditional therapies and
advancing the treatment of that risk.
Amarin Contact Information
Investor Inquiries:Lisa DeFrancescoInvestor Relations Amarin
Corporation firstname.lastname@example.org (investor
Media Inquiries:Mark MarmurCorporate Communications, Amarin
Corporation plcPR@amarincorp.com (media inquiries)
Steve Frankel / Andi Rose / Tali EpsteinJoele Frank, Wilkinson
Historical Stock Chart
From May 2023 to Jun 2023
Historical Stock Chart
From Jun 2022 to Jun 2023